2
|
Mota-Zamorano S, Robles NR, Lopez-Gomez J, Cancho B, González LM, Garcia-Pino G, Navarro-Pérez ML, Gervasini G. Plasma and urinary concentrations of arachidonic acid-derived eicosanoids are associated with diabetic kidney disease. EXCLI JOURNAL 2021; 20:698-708. [PMID: 34040498 PMCID: PMC8144539 DOI: 10.17179/excli2021-3408] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Accepted: 03/11/2021] [Indexed: 12/15/2022]
Abstract
Preclinical studies indicate that arachidonic acid (AA)-derived eicosanoids contribute to hyperglycemia-induced kidney injury. We aimed to determine whether plasma and/or urinary levels of dihydroxyeicosatrienoic (DHETs) and 20-hydroxyeicosatetraenoic (20-HETE) acids are associated with diabetic kidney disease (DKD). A total of 334 subjects (132 DKD patients and 202 non-diabetic individuals) were studied. Plasma levels of 11,12-DHET, 14,15-DHET and 20-HETE were measured by LC/MS/MS. Urinary 20-HETE concentrations were determined by immunoenzymatic assay. Subjects with normoalbuminuria had larger 20-HETE-to-creatinine urinary ratios (20-HETE/Cr) than those with micro and macroalbuminuria (p=0.012). Likewise, participants with eGFR>60 ml/min/1.73 m2 had higher plasma levels of 14,15-DHET (p=0.039) and 20-HETE/Cr ratios (p=0.007). Concentrations of 14,15-DHET, 11,12-DHET and 20-HETE/Cr were significantly lower in DKD patients. Median values for non-diabetic vs. DKD were, respectively, 493 (351.0-691.5) vs. 358 (260.5-522) ng/L, p=3e-5; 262 (183.5-356.0) vs. 202 (141.5-278.0) ng/L, p=1e-4 and 5.26 (1.68-11.65) vs. 2.53 (1.01-6.28) ng/mgCr, p=0.010. In addition, 20-HETE/Cr ratios were higher in patients with non-proteinuric DKD than in those with typical DKD (p=0.020). When only individuals with impaired filtration were considered, 14,15-DHET and 11,12-DHET levels were still higher in non-diabetic subjects (p=0.002 and p=0.006, respectively). Our results indicate that AA-derived eicosanoids may play a relevant role in DKD.
Collapse
Affiliation(s)
- Sonia Mota-Zamorano
- Department of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain
| | - Nicolás R Robles
- Service of Nephrology, Badajoz University Hospital, Badajoz, Spain
| | - Juan Lopez-Gomez
- Service of Clinical Analyses, Badajoz University Hospital, Badajoz, Spain
| | - Bárbara Cancho
- Service of Nephrology, Badajoz University Hospital, Badajoz, Spain
| | - Luz M González
- Department of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain
| | | | | | - Guillermo Gervasini
- Department of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain
| |
Collapse
|
3
|
Duflot T, Laurent C, Soudey A, Fonrose X, Hamzaoui M, Iacob M, Bertrand D, Favre J, Etienne I, Roche C, Coquerel D, Le Besnerais M, Louhichi S, Tarlet T, Li D, Brunel V, Morisseau C, Richard V, Joannidès R, Stanke-Labesque F, Lamoureux F, Guerrot D, Bellien J. Preservation of epoxyeicosatrienoic acid bioavailability prevents renal allograft dysfunction and cardiovascular alterations in kidney transplant recipients. Sci Rep 2021; 11:3739. [PMID: 33580125 PMCID: PMC7881112 DOI: 10.1038/s41598-021-83274-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Accepted: 01/27/2021] [Indexed: 12/25/2022] Open
Abstract
This study addressed the hypothesis that epoxyeicosatrienoic acids (EETs) synthesized by CYP450 and catabolized by soluble epoxide hydrolase (sEH) are involved in the maintenance of renal allograft function, either directly or through modulation of cardiovascular function. The impact of single nucleotide polymorphisms (SNPs) in the sEH gene EPHX2 and CYP450 on renal and vascular function, plasma levels of EETs and peripheral blood monuclear cell sEH activity was assessed in 79 kidney transplant recipients explored at least one year after transplantation. Additional experiments in a mouse model mimicking the ischemia–reperfusion (I/R) injury suffered by the transplanted kidney evaluated the cardiovascular and renal effects of the sEH inhibitor t-AUCB administered in drinking water (10 mg/l) during 28 days after surgery. There was a long-term protective effect of the sEH SNP rs6558004, which increased EET plasma levels, on renal allograft function and a deleterious effect of K55R, which increased sEH activity. Surprisingly, the loss-of-function CYP2C9*3 was associated with a better renal function without affecting EET levels. R287Q SNP, which decreased sEH activity, was protective against vascular dysfunction while CYP2C8*3 and 2C9*2 loss-of-function SNP, altered endothelial function by reducing flow-induced EET release. In I/R mice, sEH inhibition reduced kidney lesions, prevented cardiac fibrosis and dysfunction as well as preserved endothelial function. The preservation of EET bioavailability may prevent allograft dysfunction and improve cardiovascular disease in kidney transplant recipients. Inhibition of sEH appears thus as a novel therapeutic option but its impact on other epoxyfatty acids should be carefully evaluated.
Collapse
Affiliation(s)
- Thomas Duflot
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France.,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France.,Laboratory of Pharmacokinetics, Toxicology and Pharmacogenetics, Rouen University Hospital, 76000, Rouen, France
| | - Charlotte Laurent
- Department of Nephrology, Rouen University Hospital, 76000, Rouen, France
| | - Anne Soudey
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Xavier Fonrose
- Department of Pharmacology, Grenoble Alpes University Hospital, HP2, INSERM U1042, University of Grenoble Alpes, 38000, Grenoble, France
| | - Mouad Hamzaoui
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France.,Department of Nephrology, Rouen University Hospital, 76000, Rouen, France
| | - Michèle Iacob
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France
| | - Dominique Bertrand
- Department of Nephrology, Rouen University Hospital, 76000, Rouen, France
| | - Julie Favre
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Isabelle Etienne
- Department of Nephrology, Rouen University Hospital, 76000, Rouen, France
| | - Clothilde Roche
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - David Coquerel
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Maëlle Le Besnerais
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Safa Louhichi
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France.,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Tracy Tarlet
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France.,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Dongyang Li
- Department of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, Davis, CA, 95616, USA
| | - Valéry Brunel
- Department of General Biochemistry, Rouen University Hospital, 76000, Rouen, France
| | - Christophe Morisseau
- Department of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, Davis, CA, 95616, USA
| | - Vincent Richard
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France.,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Robinson Joannidès
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France.,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France.,Centre d'Investigation Clinique (CIC)-INSERM 1404, Rouen University Hospital, 76000, Rouen, France
| | - Françoise Stanke-Labesque
- Department of Pharmacology, Grenoble Alpes University Hospital, HP2, INSERM U1042, University of Grenoble Alpes, 38000, Grenoble, France
| | - Fabien Lamoureux
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France.,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France.,Laboratory of Pharmacokinetics, Toxicology and Pharmacogenetics, Rouen University Hospital, 76000, Rouen, France
| | - Dominique Guerrot
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France.,Department of Nephrology, Rouen University Hospital, 76000, Rouen, France
| | - Jérémy Bellien
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France. .,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France. .,Centre d'Investigation Clinique (CIC)-INSERM 1404, Rouen University Hospital, 76000, Rouen, France. .,Department of Pharmacology, Rouen University Hospital, 76031, Rouen Cedex, France.
| |
Collapse
|
4
|
Gervasini G, García-Pino G, Mota-Zamorano S, Luna E, García-Cerrada M, Tormo MÁ, Cubero JJ. Association of polymorphisms in leptin and adiponectin genes with long-term outcomes in renal transplant recipients. THE PHARMACOGENOMICS JOURNAL 2019; 20:388-397. [PMID: 31787754 DOI: 10.1038/s41397-019-0128-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Revised: 11/07/2019] [Accepted: 11/19/2019] [Indexed: 12/18/2022]
Abstract
The effect of polymorphims in leptin and adiponectin genes on long-term outcomes of renal transplantation is unknown. In 349 renal transplant recipients (RTR), we aimed to determine associations between five SNPs in the leptin receptor (LEPR) and adiponectin (ADIPOQ) genes and these outcomes. Follow-up time ranged from 2 to 25 years (mean 10.29 ± 5.16 years). Two SNPs showed associations with long-term outcomes and their statistical significance greatly increased after 39 RTR with a history of cardiovascular events prior to transplantation were removed from the analysis. Adjusted odds ratios (OR) for LEPR rs1805094 and ADIPOQ rs1501299 and risk of graft loss were 0.35 (0.16-0.74) p = 0.006 and 2.37 (1.28-4.37) p = 0.006, respectively. The assessment of risk for global mortality revealed OR values of 0.20 (0.06-0.62), p = 0.005, and 2.43 (1.08-5.44), p = 0.031 for LEPR rs1805094 and ADIPOQ rs1501299, respectively. Our results show that polymorphism in genes involved in leptin and adiponectin function modify long-term outcomes in renal transplantation.
Collapse
Affiliation(s)
- Guillermo Gervasini
- Department of Medical and Surgical Therapeutics, Medical School, University of Extremadura, Badajoz, Spain.
| | - Guadalupe García-Pino
- Department of Medical and Surgical Therapeutics, Medical School, University of Extremadura, Badajoz, Spain.,Service of Nephrology, Hospital de Zafra, Extremadura, Spain
| | - Sonia Mota-Zamorano
- Department of Medical and Surgical Therapeutics, Medical School, University of Extremadura, Badajoz, Spain
| | - Enrique Luna
- Service of Nephrology, University Hospital, Badajoz, Spain
| | | | - María Ángeles Tormo
- Deparment of Physiology, Medical School, University of Extremadura, Badajoz, Spain
| | | |
Collapse
|